Mgr. Alžbeta Katonová

Katonova A., Andel, R., Jurasova, V. Veverova K., Borovska S., Horakova H., Kolarova T., Matoska V., Vyhnalek M., Hort J. (2025). KLOTHO-VS heterozygosity, α-klotho protein levels and cognitive performance in Alzheimer’s disease. Alzheimer’s Research & Therapy. 17, 234. IF₂₀₂₄ = 7.6 (Q1, D1)

Angelucci F., Nedelska Z., Napravnikova Manová B., Katonova A., Jurášová V., Svetlikova D., Vyhnálek M., Hort J. (2025). Dementia with Lewy Bodies (DLB), Parkinson’s Disease (PD), and Multiple System Atrophy (MSA) Are Synucleopathies Characterized by Increased Serum Levels of Plasminogen Activator Inhibitor-1 (PAI-1). ACS Omega. 10, 23:24194–99. IF₂₀₂₄ = 4.3 (Q2)

Katonova A., Andel R., Jurasova V., Veverova K., Angelucci F., Matoska V., Hort J. (2025). Associations of KLOTHO-VS heterozygosity and alpha-klotho protein with cerebrospinal fluid Alzheimer’s disease biomarkers. Journal of Alzheimer’s Disease. 0, 0. IF₂₀₂₃ = 3.4 (Q2)

Veverova K. ^#, Katonova A. ^#, Horakova H., Laczo J., Angelucci F., Hort J., Lautrup S., Fei Fang E., Vyhnalek M. (2025). Distinctive autophagy/mitophagy biomarker profiles in frontotemporal lobar degeneration and Alzheimer's disease. Acta Neuropathologica Communications. 13, 37. IF₂₀₂₃ = 6.2 (Q1, D1)

Jurasova V., Andel R., Katonova A., Nolan R., Lacinova Z., Kolarova T., Matoska V., Vyhnalek M.., Hort J. (2024). Is KIBRA polymorphism associated with memory performance and cognitive impairment in Alzheimer’s disease? Journal of Alzheimer’s Disease. 102, 1, 218-227. IF₂₀₂₃ = 3.4 (Q2)

Jurasova V., Andel R., Katonova A., Veverova K., Zuntychova T., Horakova H., Vyhnalek M., Kolarova T., Matoska V., Blennow K., Hort J. (2024). CSF neurogranin levels as a biomarker in Alzheimer's disease and frontotemporal lobar degeneration: a cross-sectional analysis. Alzheimers Research Therapy. 16, 1, 199. IF₂₀₂₃ = 8.0 (Q1, D1)

Veverova, K., Laczo, J., Katonova, A., Horakova, H., Matuskova, V., Angelucci, F., Laczo, J., Nedelska, Z., Hort, J., Wang, H-L-., Zhang, J., Shi, L., Fang, E. F., Vyhnalek, M. (2024). Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer's disease. Autophagy. 1-11. IF₂₀₂₃ = 14.6 (Q1, D1)

Angelucci, F., Veverova, K., Katonova, A., Vyhnalek, M., Hort, J. (2024) Plasminogen activator inhibitor-1 serum levels in frontotemporal lobar degeneration. Journal of Cellular and Molecular Medicine. 5, 28, e18013. IF₂₀₂₃ = 4.3 (Q2)

Angelucci, F., Veverova, K., Katonova, A., Vyhnalek, M., Hort, J. (2023). Alzheimer's Disease Serum PAI-1/BDNF ratio is increased in Alzheimer’s disease and correlates with disease severity. ACS Omega. 8, 39, 36025–36031. IF₂₀₂₃ = 3.7 (Q2)

Katonova, A., Sheardova, K., Amlerova, J., Angelucci, F., Hort, J. (2022). Effect of a vegan diet on Alzheimer's disease. International Journal of Molecular Sciences. 23. 14924. IF₂₀₂₃ = 4.9 (Q1)

Angelucci, F., Veverova, K., Katonova, A., Piendel, L., Vyhnalek, M., Hort, J. (2022). Alzheimer's disease severity is associated with an imbalance in serum levels of enzymes regulating plasmin synthesis. Pharmaceuticals. 15, 1074. IF₂₀₂₃ = 4.3 (Q2)